| Schedule Of Segment Reporting Information |
| |
|
Consumer Products Segment |
|
Specialty Pharmaceutical Segment |
|
Consolidated Totals |
| Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
| June 30, 2018: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales, net |
|
$ |
12,348,695 |
|
|
$ |
– |
|
|
$ |
12,348,695 |
|
| Gross profit |
|
|
9,060,076 |
|
|
|
– |
|
|
|
9,060,076 |
|
| Selling, general and administrative |
|
|
(5,319,536 |
) |
|
|
(1,068 |
) |
|
|
(5,320,604 |
) |
| Research and development |
|
|
(75,833 |
) |
|
|
(366,171 |
) |
|
|
(442,004 |
) |
| Operating income (loss) |
|
$ |
3,664,707 |
|
|
$ |
(367,239 |
) |
|
$ |
3,297,468 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Three Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
| June 30, 2017: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales, net |
|
$ |
4,081,832 |
|
|
$ |
– |
|
|
$ |
4,081,832 |
|
| Gross profit |
|
|
2,844,458 |
|
|
|
– |
|
|
|
2,844,458 |
|
| Gain on change in derivative liabilitis |
|
|
27,288 |
|
|
|
– |
|
|
|
27,288 |
|
| Selling, general and administrative |
|
|
(3,447,786 |
) |
|
|
(77,987 |
) |
|
|
(3,525,773 |
) |
| Research and development |
|
|
(55,956 |
) |
|
|
(149,691 |
) |
|
|
(205,647 |
) |
| Operating loss |
|
$ |
(631,996 |
) |
|
$ |
(227,678 |
) |
|
$ |
(859,674 |
) |
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Six Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
| June 30, 2018: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales, net |
|
$ |
20,419,460 |
|
|
$ |
– |
|
|
$ |
20,419,460 |
|
| Gross profit |
|
|
14,621,979 |
|
|
|
– |
|
|
|
14,621,979 |
|
| Selling, general and administrative |
|
|
(10,046,120 |
) |
|
|
(15,077 |
) |
|
|
(10,061,197 |
) |
| Research and development |
|
|
(192,467 |
) |
|
|
(403,241 |
) |
|
|
(595,708 |
) |
| Operating income (loss) |
|
$ |
4,383,392 |
|
|
$ |
(418,318 |
) |
|
$ |
3,965,074 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| Six Months Ended |
|
|
|
|
|
|
|
|
|
|
|
|
| June 30, 2017: |
|
|
|
|
|
|
|
|
|
|
|
|
| Product sales, net |
|
$ |
7,846,023 |
|
|
$ |
– |
|
|
$ |
7,846,023 |
|
| Gross profit |
|
|
5,277,462 |
|
|
|
– |
|
|
|
5,277,462 |
|
| Gain on change in derivative liabilities |
|
|
237,888 |
|
|
|
– |
|
|
|
237,888 |
|
| Royalty buy-out |
|
|
– |
|
|
|
(2,432,000 |
) |
|
|
(2,432,000 |
) |
| Selling, general and administrative |
|
|
(7,052,962 |
) |
|
|
(149,520 |
) |
|
|
(7,202,482 |
) |
| Research and development |
|
|
(104,989 |
) |
|
|
(289,374 |
) |
|
|
(394,363 |
) |
| Operating loss |
|
$ |
(1,642,601 |
) |
|
$ |
(2,870,894 |
) |
|
$ |
(4,513,495 |
) |
|